---
title: "Precision ApS – Regnskab 2025 og nøgletal"
description: "Precision ApS (CVR 44911930). Regnskabsperiode: 2025-01-01 – 2025-12-31. Bruttofortjeneste -895,3 t DKK, årets resultat -965 t DKK, egenkapital 18,1 mio. DKK."
canonical_url: "https://datapublica.dk/companies/44911930-precision-aps/financials"
locale: "da"
route_type: "company_financials"
robots: "index,follow"
content_access: "standard"
---

# Precision ApS — Regnskab

Precision ApS \(CVR 44911930\). Regnskabsperiode: 2025-01-01 – 2025-12-31. Bruttofortjeneste -895,3 t DKK, årets resultat -965 t DKK, egenkapital 18,1 mio. DKK.

CVR 44911930

## Seneste regnskabsperiode

- 2025 • 2025-01-01 • 2025-12-31 • entity • DKK • -895254 • -965035 • 20486870 • 18129328 • 0

## Regnskabshistorik

- 2024 • 2024-06-17 • 2024-12-31 • entity • DKK • -25000 • -58748 • 5977915 • 4208382 • 0

## Højdepunkter fra årsrapporten

- primary activities • The purpose of the company is to operate as an investment business and engage in related activities, as well as to serve as a holding company for subsidiaries. • entity

- going concern uncertainty • The Company’s subsidiary, 2cureX A/S, has incurred losses and is dependent on additional financing to continue its operations. 2cureX A/S incurred a loss of DKK 17.5 million in 2025 and had negative equity of DKK 0.2 million at 31 December 2025. 2cureX A/S’ continued operations depend on additional financing, including completion of a planned transaction and related convertible loan financing. These matters are subject to conditions outside 2cureX A/S’ control, and therefore a material uncertainty exists that may cast significant doubt on 2cureX A/S’ ability to continue as a going concern.Precision ApS has issued a letter of financial support to 2cureX A/S, valid until the annual report of 2cureX A/S for 2026 has been approved and published. Management expects that 2cureX A/S will obtain other financing and that the letter of support will not be utilised. However, if the financing is not completed and the support is utilised, this may require funding from Precision ApS beyond its current liquidity resources.Accordingly, a material uncertainty exists that may cast significant doubt on the Company’s ability to continue as a going concern. Management has concluded that the going concern basis of accounting remains appropriate, and the Financial Statements have been prepared on that basis. • entity

- recognition measurement uncertainty • The Company’s investment in its subsidiary, 2cureX A/S, is recognised at DKK 19,007,331 at 31 December 2025. Investments in subsidiaries are measured at cost or, where cost exceeds the recoverable amount, at this lower value.The recoverable amount of the investment depends on 2cureX A/S’ ability to continue as a going concern and to complete the planned financing described in Note 1. Management has assessed that no impairment is required at 31 December 2025.However, due to the material uncertainty regarding 2cureX A/S’ ability to continue as a going concern, there is uncertainty relating to the recognition and measurement of the investment. If 2cureX A/S is unable to complete the planned financing or continue its operations, the investment may not be recoverable in full, and a material impairment loss may be required. • entity

- contingent liabilities • Other contingent liabilities

The Company has issued a letter of support for its subsidiary, 2cureX A/S, which will remain valid until the subsidiary's statutory financial statements for 2026 are approved.

The Danish group companies are jointly and severally liable for tax on the jointly taxed incomes etc of the Group. The total amount of corporation tax payable by the Group amounts to DKK 0. Moreover, the Danish group companies are jointly and severally liable for Danish withholding taxes by way of dividend tax, tax on royalty payments and tax on unearned income. Any subsequent adjustments of corporation taxes and withholding taxes may increase the Group’s liability.

Other financial obligationsAs of 31 December 2025, the company has no other financial obligations. • entity